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ABSTRACT  
Background 
Acute kidney injury (AKI) can occur rarely in patients exposed to iodinated contrast 
and result in contrast-induced AKI (CI-AKI). A key risk factor is the presence of pre-
existing chronic kidney disease (CKD), therefore it is important to assess patient risk 
and obtain kidney function measurement prior to administration. Point of care (PoC) 
testing provides an alternative strategy but there remains uncertainty, with respect to 
diagnostic accuracy and clinical utility. 
 
Methods 
A device study compared three PoC analysers (Nova StatSensor, Abbott i-STAT, 
Radiometer ABL800 FLEX) with a reference laboratory standard (Roche Cobas 8000 
series, enzymatic creatinine). Three hundred adult patients attending a UK hospital 
phlebotomy department were recruited to have additional blood samples for analysis 
on the PoC devices.  
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Results 
The ABL800 FLEX had the strongest concordance with laboratory measured serum 
creatinine (mean bias=-0.86, 95% limits of agreement = -9.6 to 7.9) followed by the i-
STAT (average bias=3.88, 95% limits of agreement = -8.8 to 16.6) and StatSensor 
(average bias=3.56, 95% limits of agreement = -27.7 to 34.8). In risk classification, 
the ABL800 FLEX and i-STAT identified all patients with an eGFR≤30, whereas the 
StatSensor resulted in a small number of missed high-risk cases (n=4/13) and also 
operated outside of the established performance goals. 
 
Conclusions 
The screening of patients at risk of CI-AKI may be feasible with PoC technology. 
However in this study it was identified that the analyser concordance with the 
laboratory reference varies. It is proposed that further research exploring PoC 
implementation in imaging department pathways is needed. 
 
Trial registration 
ISRCTN18805212 
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Point of care creatinine testing for kidney function measurement prior to 
contrast-enhanced diagnostic imaging: Evaluation of the performance of three 
systems for clinical utility 
 
INTRODUCTION 
The use of intravascular iodinated contrast agents is common in diagnostic imaging 
but the benefits of their use must be weighed against the potential risk [1]. Patients 
with pre-existing chronic kidney disease (CKD) and other factors, such as diabetes, 
may be at risk of developing acute kidney injury (AKI) following contrast 
administration. Contrast-induced AKI (CI-AKI) has been defined as AKI occurring 24-
72 hours after the intravascular administration of iodinated contrast media that 
cannot be attributed to other causes [2]. Where the contrast may be one of a number 
of other additional attributable factors post intervention the term post contrast AKI 
(PC-AKI) may be more appropriate [3]. To minimise the risk of this potentially fatal 
complication, several international guidelines [1,4-9] recommend patient screening 
and kidney function testing. In the out-patient setting, the estimated glomerular 
filtration rate (eGFR), calculated from the serum creatinine (SCr) is used to risk 
stratify patients prior to contrast administration.  Historically, most guidelines have 
traditionally advised that an eGFR below 60mL/min/1.73m2 signifies an increased 
risk of CI-AKI triggering strategies aimed at optimising volume status with 
prophylactic oral hydration or intravenous (IV) volume expansion. The highest risk 
group is considered to be in patients with an eGFR below 30mL/min/1.73m2 [1], 
which may, in some health systems result in restriction of iodinated contrast 
altogether. Despite variation in clinical practice internationally [10-13] regarding the 
best way to calculate a patients individual risk and which prevention strategies to 
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implement, testing of kidney function prior to administration of iodinated contrast is 
uniformly accepted as standard practice.  
Point of care (PoC) testing for kidney function is an attractive method for providing a 
rapid result, particularly in the emergency department, acute medical unit or critical 
care setting where there is a need to make immediate decisions regarding treatment. 
With ever increasing demands on health services globally, it has been explored as a 
strategy to ensure patient safety before the administration of contrast media [14-25]. 
However, the literature reveals both disparity in clinical concordance with the central 
laboratory and the clinical utility of PoC in clinical practice and adoption has therefore 
been limited [10]. Importantly, even where they are available in diagnostic imaging 
departments, such devices have been widely integrated into the clinical pathway. 
There remains an important need to formally evaluate the role of PoC testing in 
terms of accuracy, clinical feasibility, and health economic benefits.  
 
Aims of this investigation 
This Bias Estimation of Point of Care Creatinine (BEPoCC ISRCTN 18805212) 
sought to compare the performance of 3 CE-marked PoC analysers against a 
reference laboratory standard to confirm the accuracy of kidney function 
categorisation and assess their validity for clinical decision making in diagnostic 
imaging.   
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MATERIALS AND METHODS 
Study participants 
Over a six-week period in September and October 2016, consecutive adult 
outpatients (≥18years) attending a UK hospital phlebotomy department for routine 
Urea and Electrolytes (U&E) blood tests were approached. No upper age limit was 
adopted, but pregnant individuals and those unable to consent were excluded. 
Following consent, participants completed a screening questionnaire based on 
previous studies [22,26,27] to examine patients kidney risk status and stratify the 
sample into low and high risk groups based on their co-morbidities and medication. 
This stratification method ensured the study sample comprised patients with a range 
of kidney function levels to ensure applicability to a diagnostic imaging setting. The 
PoC results were not reported to the referring clinician and did not influence any 
clinical decisions. Demographics, including age, gender and race (Afro-Caribbean or 
not Afro-Caribbean) were collected for each participant. 
Method agreement is a question of estimation, not hypothesis testing. In this 
scenario there is no ‘minimum’ sample size required. The confidence interval for 
95% limits of agreement is +/- 1.96 √(3/n)s, where n is the sample size and s is the 
standard error [28]. Therefore, a sample size of 300 provides a 95% CI of 
approximately +/- 0.2s. 
 
Ethics 
The research complied with all the relevant regulations, institutional policies and in 
ran in accordance to the tenents of the Helsinki Declaration. Ethical approval for the 
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study was granted by South East Scotland Research Ethics Committee 
(IRAS:202240) and all participants gave written informed consent.  The study was 
adopted onto the NIHR portfolio (CPMS ID: 31955).  
 
Blood sampling 
The standard U&E blood sample was collected by an experienced phlebotomist and 
processed following local operating procedures. To ensure minimal patient 
intervention, an additional sample of blood was immediately collected from the same 
venous puncture site. The whole blood research sample (S-Monovette Lithium 
Heparin 2.7mL tube, Ref 05.1553, Sarstedt, Numbrecht, Germany) was labelled with 
a unique study identifier and transferred to the on-site laboratory for analysis.  
 
Capillary blood sampling was subsequently performed from the fingertip of each 
participant by two research radiographers (BS & MAH), as would be the case in 
routine practice. The skin was pierced with a spring-loaded lancet and the sample 
collected directly onto the analysis strip avoiding squeezing of the finger or milking of 
blood. 
Phlebotomy and laboratory staff were unaware of the patients’ eGFR, reference 
method results and other PoC results at the time of sample collection and analysis. 
Where there was incomplete data, i.e. results not available across all methods, the 
participants were excluded from the sample.   
 
 
 
 
7 
 
Test methods 
The reference standard was Roche Modular IDMS calibrated enzymatic creatinine 
analysis, performed on serum samples on a Cobas8000 platform (Roche, Inc., 
Mannheim, Germany).  During the study period, for the five creatinine analysers on 
the reference laboratory platform, the between-run imprecision was determined 
using independent commercially available QC materials, the standard practice in the 
laboratory. CVs ranged from 1.3-2.1% (median=1.8%) at a concentration of 81 
µmol/L, 1.0-1.4% (median=1.4%) at concentration of 203 µmol/L and 0.9-1.3% 
(median 1.2%) at a concentration of 615 µmol/L.  
 
The CE-marked PoC analysers were the StatSensor (Nova Biomedical, Waltham, 
MA, USA) and i-STAT (Abbott Laboratories, Princeton, NJ, USA), both handheld 
devices in current use in UK imaging departments and the ABL800 FLEX 
(Radiometer, Brønshøj, Denmark), a benchtop analyser. Capillary blood samples 
were analysed on the StatSensor in the phlebotomy department. Due to the larger 
volume requirements, whole blood samples were analysed on the i-STAT and 
ABL800 FLEX devices which were situated in the laboratory due to space 
constraints. Each PoC analyser employs a creatinine method based on the 
amperometric detection of H2O2 generated by three enzyme cascade reactions and 
expresses plasma calibrated patient results. To avoid inter-device variation, a single 
analyser was used from each manufacturer for the duration of the study. Quality 
control (QC) was performed daily during the research using the manufacturers’ 
quality control materials and limits of acceptability for imprecision. 
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The laboratory SCr result was confirmed from the hospital order communication 
system, as in routine practice. The PoC whole blood creatinine (WBCr) result was 
documented for each participant. No off-set adjustment was applied for PoC 
measurements. All results were transcribed into the EDGE research management 
system (University of Southampton, UK Version 2.0.28) and exported to Excel® 
(Microsoft Corporation) for initial analysis. For consistency, the eGFR for all PoC 
devices were derived using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation [29], taking account of race and gender. In addition, the 
Modification of Diet in Renal Disease (MDRD) study equation [30] was also used to 
calculate an alternative eGFR level for comparison. 
 
Statistical Analysis 
In the absence of repeated patient sample measurements from each PoC device, 
imprecision, expressed as coefficient of variation (CV), was calculated based on the 
daily analysis of quality control material. We report the mean, standard deviation 
(SD) and range across the patient samples for each device. We also report, and 
illustrate using Bland-Altman plots, the mean bias of the PoC devices relative to the 
laboratory reference standard along with the 95% limits of agreement for the 
differences. Passing-Bablok regression analyses explore the presence of 
proportional and constant error for each of the three devices (from the slope and 
intercept co-efficient, respectively). This approach does not assume that any 
measurement error in either the laboratory or PoC measurements is normally 
distributed. 
Total analytical error was calculated in line with Clinical & Laboratory Standards 
Institute (CLSI) recommendations [31]: 
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𝑇. 𝐴. 𝐸 =  𝑥 ̂ ± (𝑡 ∗ 𝑠. 𝑑. ) 
Where ?̂? is the average difference, 𝑠. 𝑑. is standard deviation of the differences, and 𝑡 
is a factor from a t-distribution (in this case, 1.65). Further to this, we assessed 
whether the derived eGFR measurements from each device meet the performance 
goal set by The Laboratory Working Group of the National Kidney Disease Education 
Program (NKDEP): that the average error in eGFR should not exceed 10% [32]. 
  
The eGFR results calculated using the CKD-EPI equation were categorised 
according to the associated risk of CI-AKI [1] using predefined categories (high 
risk=≤30; moderate=31-59; low=≥60). Overall clinical concordance was calculated as 
the number (%) of samples falling into the same CI-AKI risk category as that derived 
from the laboratory method. To evaluate clinical utility, eGFR values calculated from 
PoC devices were also compared to the laboratory derived eGFR values through 
error grid analysis [33], which visually demonstrates a scatter plot of both methods 
into clinically relevant areas.  
The analyses and plots were generated using the Analyse-It add-in (Analyse-it 
Software Ltd, Leeds, UK) for Excel® (Microsoft Corporation, USA) and the statistical  
software package R (The R Foundation, https://www.r-project.org/).  
 
RESULTS 
Quality control/Device imprecision 
The daily QC confirmed that all measurements were within the ranges given by the 
manufacturer for each device prior to analysis of participant samples (Table 1). 
Variation in the number of QC samples analysed relates to automatic daily QC with 
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the ABL800 FLEX and manual QC for the handheld analysers on recruitment days 
only. 
 
Table 1. Summary of PoC quality control replication data 
 i-STAT StatSensor ABL800 FLEX 
QC sample Level 1 Level 3 Level 1 Level 3 Level 1 Level 2 High 
Reference 
mean (range)* 
380  
(309-451) 
44  
(09-80) 
(44-124) (398-
663) 
(211-
291) 
(21-37) 1500 
Mean  
µmol/L 
384.9 47.6 80.9 496.5 243.8 29 1547.8 
SD  
µmol/L 
9.3 2.4 6.4 35.8 3.6 0.6 27.7 
CV  
% 
2.3 5 7.9 7.2 1.5 2.1 1.8 
N 26 26 25 25 53 54 60 
 
Key: QC=quality control; CV=coefficient of variation; N=number of samples; *values supplied by 
individual manufacturers for their QC materials. 
 
 
 
Participant Demographics  
A total of 363 individuals consented to complete the screening questionnaire. Of 
these, 63 were subsequently excluded prior to allocation to the relevant study arm, 
resulting in 300 participants proceeding to intervention (supplementary figure 1).  
The study sample comprised 158 males and 142 females, with 3 individuals (1.0%) 
defining their race as Afro-Caribbean. The age range was 18-92 years with a mean 
of 60 years (SD ±18 years).  
The participants were stratified into high (n=200) and low-risk (n=100) arms based 
on the result of the screening questions. A range of risk factors were identified, 
including previous abnormal kidney function or kidney disease, older age, 
hypertension, heart disease, gout, use of anti-inflammatories, chemotherapy or other 
nephrotoxic drugs and multiple myeloma.  
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Test failure 
A total of 5 procedural failures were recorded during the study, 4 with the StatSensor 
and 1 with the ABL800 FLEX. No failures were recorded for the i-STAT. In relation to 
the StatSensor, 2 of the 4 failures were due to flow errors during sampling, one was 
due to the strip not being located correctly, and the other related to the machine 
timing out due to inactivity. In all cases, a second test was successful. The ABL800 
FLEX failure was due to an incorrectly sited syringe during processing of the sample. 
The second attempt to analyse the same sample was completed successfully.  
 
Participant samples 
A summary of the creatinine concentrations for each participant sample measured by 
the laboratory reference standard and each of the 3 PoC devices is reported in Table 
2.  
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Table 2 Descriptive and method comparison statistics for patient creatinine values (PoC 
devices compared with the laboratory reference standard) 
 
All PoC devices demonstrated both positive and negative bias versus the laboratory 
results over the range of patient creatinine values measured (Table 2 and 
supplementary figures 2-4). The i-STAT and StatSensor both demonstrated a small 
positive average bias, although this was predominantly at higher creatinine with the i-
STAT. Whereas, the ABL800 FLEX demonstrated a marginal negative average bias, 
but had the tightest 95% limits of agreement of the three devices.  
 
The constant and proportional error for each PoC device compared to the laboratory 
reference standard is reported, estimated based on the Passing-Bablok regression 
models.  
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Clinical relevance 
Calculation of eGFR  
The average total error for eGFR calculated from the WBCr measurements for the i-
STAT and ABL800 FLEX when compared to those from the laboratory reference 
standard were less than the desired 10% error goal (5.5% and 5.0%, respectively). 
The average total error for the StatSensor exceeded this goal (13.6%).  
 
When eGFR results, derived from the reference standard laboratory SCr, were 
categorised according to the potential risk of CI-AKI and a subsequent need for the 
initiation of preventative measures, there was variation between the outcomes when 
using the CKD-EPI and MDRD calculations (Table 3). When risk stratifying into high 
and moderate vs. low risk, CKD-EPI and MDRD agreed for 94.2% of individuals. In 
5% of cases, the MDRD calculations overestimated the risk and therefore would 
have resulted in unnecessary preventative measures being applied. In the remaining 
3 cases the risk was underestimated, although the results were close to the cut-off 
values. 
 
Table 3 Comparison of the eGFR result from laboratory reference standard serum creatinine 
using the CKD-EPI and MDRD equations 
  MDRD 
High Moderate Low Total 
C
K
D
-E
P
I 
High 12 1 - 13 
Moderate 1 59 2 62 
Low - 14 211 225 
Total 13 74 213 300 
Key: High=eGFR≤30; Moderate=eGFR31-59; Low=≥60 
 
 
14 
 
Error grid analysis 
When identifying patients with an abnormal kidney function (eGFR<60), i-STAT 
WBCr results and ABL800 FLEX WBCr results showed 98.6% (n=74/75) and 97.3% 
(n=73/75) concordance respectively with the laboratory SCr results, whilst 
StatSensor WBCr results showed 89.3% (n=67/75) concordance.  
In relation to those at highest clinical risk where contrast may be withheld 
(eGFR≤30), clinical concordance with the laboratory reference standard the results 
were similar (i-STAT n=13/13; 100%; ABL800 FLEX n=13/13; 100.0%; StatSensor 
n= 9/13; 69.2%).  
When the CKD-EPI eGFR values were grouped according to the risk of CI-AKI all 
PoC devices resulted in the risk of CI-AKI being over- or under-estimated in a small 
number of patients in comparison to the laboratory reference standard (table 4).  
Error grids (Figure 1a-c) demonstrate performance zones for risk categorisation 
based on the CKD-EPI eGFR calculations. The number of participants placed in 
each zone and the patient management repercussions of risk misclassifications are 
summarised in Table 4.   
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Figure 1: Error grid analysis of concordance between eGFR risk stratification derived from 
laboratory measured serum creatinine and 3 POC devices (1a= i-STAT, 1b= StatSensor, 1c= 
ABL800 FLEX). Zones relating to patient management repercussions are highlighted and 
related data is summarised in Table 4.  
 
 
 
Table 4: Patient management implications of concordance between eGFR risk stratification 
based on UK guidelines during data collection [1] 
 
Zone Implication on Management Decision i-STAT  
No (%) 
StatSensor 
No (%) 
ABL800 FLEX 
No (%) 
A Correct risk classification – appropriate 
management 
282 (94.0) 250 (83.3) 297 (99.0) 
B Incorrectly classified, but no implication 
for clinical management  
16 (5.3) 42 (14.0) 3 (1.0) 
C Incorrect classification, potential for 
unnecessary prophylaxis or with-holding 
of contrast  
2 (1.0) 4 (1.3) 0 
D Incorrect classification and potential for 
increased risk of CI-AKI due to 
insufficient prophylaxis 
0 4 (1.3) 0 
 
DISCUSSION 
Clinical practice guidelines recommend targeted screening of kidney function based 
on individual risk [7,8]. However, due to the silent nature of many forms of kidney 
disease and complex workflows within diagnostic imaging, it is usual practice for all 
patients receiving iodinated contrast-enhanced imaging to have had a SCr and 
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eGFR checked prior to the examination [10-13]. This result establishes whether it is 
safe for a patient to receive iodinated contrast media and identify if any preventative 
measures are required or whether contrast media is withheld. It is therefore very 
important that the kidney function result is available and that this is accurate and 
reliable. In practice, problems with availability of a kidney function result can lead to 
significant implications for patients in terms of delay in diagnosis and reduction in 
service efficiency [10,15]. These issues may be addressed by the introduction of 
PoC technology. 
 
The i-STAT and the StatSensor have been evaluated most frequently in the 
diagnostic imaging literature [14-25] and are available in a small number of clinical 
departments across the UK [10]. The sampling techniques used in this study mirror 
how they are being used in practice. The results confirm that kidney function testing 
is feasible on a PoC device but variation in clinical concordance between the devices 
tested and the laboratory reference standard was evident similar to previous 
research [14]. The ABL800 FLEX analyser was the most precise of the three with the 
lowest total analytical error, closely followed by the i-STAT. The StatSensor fared 
worst in both categories and failed to identify a small proportion of high-risk patients. 
The capillary samples were taken by fingerprick, which may have contributed to the 
analytical error during participant testing. Crucially this study evaluated clinical 
performance which establishes whether the test can identify individuals with pre-
defined criteria or conditions within a particular clinical context [34]. In line with other 
recent studies [14,17,22,24,35] the ABL800 FLEX or i-STAT may be appropriate for 
use in this context, whereas the StatSensor results were outside the recommended 
performance goals for eGFR [32].   
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The CKD-EPI creatinine equation has been recommended to estimate GFR, using 
creatinine assays with calibration traceable to the standardised reference material 
[36]. Our study confirmed previous evidence of variation in eGFR calculation when 
using the two different equations [37], with over-estimation of CI-AKI risk with MDRD 
in some patients [38, 39]. Although, only the laboratory differences are reported, this 
pattern would be seen across methods. In clinical practice for PoC devices with an 
inbuilt eGFR calculator this confirms the importance of ensuring that the equation 
used (CKD-EPI or MDRD) is aligned to the local laboratory. Importantly, this also 
identifies the relevance of cross-laboratory standards where patient results are 
shared but different calculation standards are used. 
 
This study, which is the first to utilise error grid analysis for eGFR based clinical 
outcomes, demonstrated that PoC analysers aligned the majority of participant 
samples to the correct CI-AKI risk category and reassuringly no high-risk cases 
would have been missed with two of the 3 PoC devices.  
The need for efficient workflow and rapid turn-around of contrast-enhanced 
diagnostic imaging studies supports the introduction of PoC creatinine testing [15, 
22]. However, due to previous concerns around the accuracy of PoC creatinine 
technology, it is yet to make its way into mainstream use. Further evidence is 
required of the feasibility and practicality of embedding this technology into clinical 
practice.   
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Robustness of findings 
This study was conducted in a phlebotomy setting and the patients may not wholly 
represent those referred for contrast-enhanced imaging. Despite the stratification of 
participants, only one quarter of samples in the present study demonstrated an 
abnormal kidney function (eGFR<60), however this is comparable with other studies 
[14,25] and considered a sufficient spread to review the appropriateness of PoC for 
clinical practice in the diagnostic imaging context. 
 
This was not a formal method evaluation study, as required for introduction into 
routine practice but focussed on exploring the clinical impact of using POCT 
compared to use of the laboratory. The study was limited to the assessment of bias, 
total error and clinical performance of the devices in relation to creatinine and eGFR. 
Precision, interference, cross-reactivity, linearity and quantitation limits of PoC 
analysers have not been investigated and are outside the scope of this study. The 
analytical goal for total allowable error in creatinine measurements is derived from 
repeated measurements, which was not possible in this study. The analysis is 
therefore limited to reporting the total analytical error and the performance goal for 
eGFR was defined as the key outcome. 
 
Comparisons were made using the recommended CKD-EPI creatinine equation and 
an IDMS calibrated enzymatic creatinine assay, however both the MDRD equation 
and creatinine assays based on the Jaffe reaction are still being used in a number of 
laboratories [10]. Concordance between PoC and eGFR determined in these 
laboratories may differ from our findings. 
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Procedure failure rates have been reported but other practical factors, such as ease 
of device maintenance and pros and cons of bedside capillary vs venous whole 
blood sampling, were not explored further. The cost of PoC implementation has not 
been investigated in this study, however variations in the initial and ongoing costs of 
devices will vary depending on type (hand held vs benchtop) and volume of samples 
analysed [40]. 
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Supplementary figures 
 
Supplementary figure 1: Recruitment flow chart  
 
 
 
 
Supplementary figure 2(A) Scatter diagram of the difference versus the means of paired 
creatinine results analysed with the i-STAT and reference method creatinine.  
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Supplementary figure 2(B) Scatter diagram mapping the creatinine results from the i-STAT to 
the laboratory measurements, with Passing-Bablok line and equation 
 
 
 
Supplementary figure 3(A) Scatter diagram of the difference versus the means of paired 
creatinine results analysed with the StatSensor and reference method creatinine.  
 
 
 
 
Supplementary figure 3(B) Scatter diagram mapping the creatinine results from the StatSensor 
to the laboratory measurements, with Passing-Bablok line and equation 
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Supplementary figure 4(A) Scatter diagram of the difference versus the means of paired 
creatinine results analysed with the ABL800 FLEX and reference method creatinine.  
 
 
 
Supplementary figure 4(B) Scatter diagram mapping the creatinine results from the ABL800 
FLEX to the laboratory measurements, with Passing-Bablok line and equation 
 
 
 
